893566-16-0

Usage

Uses

Used in Medicinal Chemistry:
Exo-3-Boc-6-aminomethyl-3-azabicyclo[3.1.0]hexane is used as a building block in the synthesis of various pharmaceutical compounds due to its unique structure and functional groups. The Boc protecting group allows for selective reactions to occur at other sites on the molecule, while the aminomethyl group can be further modified or used for conjugation to other molecules, enhancing the compound's pharmacological properties.
Used in Drug Discovery:
exo-3-Boc-6-aminomethyl-3-azabicyclo[3.1.0]hexane is utilized as a potential lead molecule in drug discovery efforts, particularly for the development of new therapeutic agents. The presence of the Boc protecting group and the aminomethyl group may allow for the design of drugs with specific binding affinities to target proteins or enzymes, leading to the modulation of biological pathways and the treatment of various diseases.
Used in Chemical Synthesis:
Exo-3-Boc-6-aminomethyl-3-azabicyclo[3.1.0]hexane serves as an intermediate in the synthesis of more complex organic compounds. The Boc group can be selectively removed under mild conditions, revealing the free amine, which can then participate in further reactions. This property makes it a valuable component in the preparation of a wide range of chemical products, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
exo-3-Boc-6-aminomethyl-3-azabicyclo[3.1.0]hexane is employed as a research tool in the study of biological processes and the development of new chemical methodologies. Its unique structure and functional groups make it an interesting subject for investigations into the mechanisms of protein-ligand interactions, enzyme inhibition, and other biological phenomena. Additionally, its use in the development of new synthetic methods and strategies can contribute to the advancement of organic chemistry and its applications in various fields.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 134575-13-6 (1α,5α,6α)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane 
• 850808-43-4 tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 419572-18-2 (1R,5S,6r)-tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 871727-08-1 (3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)methanol 
• 289037-48-5 (3-azabicyclo[3.1.0]hex-6-yl)methanol 

Relevant academic research and scientific papers

FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to nicotinamide phosphoribosyltransferase (NAM FT) expression. More particularly, this disclosure relates to fused bicyclic heterocyclic compounds and pharmaceutical compositions thereof, methods of inhibiting NAM FT with these compounds, and methods of treating diseases related to NAMPT expression.

AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.

Synthesis and SAR of Imidazo[1,5-a[pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease

Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people. The need for improved AD therapies is unmet. The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders associated with AD. Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivatives as 5-HT4R partial agonists. The focused SAR, optimization of ADME properties resulted the discovery of compound 5a as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compound with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.

INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptor agonists.